Skip to main content
SpringerLink
Log in

Interdisziplinäre Leitlinien: Entzündliche Darmerkrankungen — M. Crohn, Colitis ulcerosa

Interdisciplinary Guidelines: Inflammatory Bowel Diseases — Crohn’s Disease, Ulcerative Colitis

  • Conference paper
Klinik und Forschung in der Chirurgie unter dem Aspekt von Effizienz und Ökonomie

Part of the book series: Langenbecks Archiv für Chirurgie ((KONGRESSBAND,volume 1997))

  • 14 Accesses

Summary

Guidelines for medical, nutritional, and surgical treatment of Crohn’s disease have been drawn up recently by gastroenterologists and abdominal surgeons from the “Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten”. These data have not yet been published, but are presented here. Medical treatment of ulcerative Colitis during acute attacks and remission depends widely on the extent and activity of the disease. Recently published guidelines for surveillance of patients with long-lasting ulcerative Colitis to prevent colorectal cancer by American gastroenterologists and surgeons are discussed.

Zusammenfassung

Leitlinien zur medikamentösen und Ernährungstherapie sowie zur operativen Therapie des Morbus Crohn wurden Ende 1996 von Gastroenterologen und Chirurgen durch die Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten erarbeitet. Obwohl noch nicht offiziell publiziert, werden diese Richtlinien diskutiert. Die konservative Therapie der Colitis ulcerosa während des akuten Schubes und in der Remission hängt wesentlich vom Schweregrad und Ausdehnung der Erkrankung ab. Kürzlich publizierte Leitlinien amerikanischer Gastroenterologen und Chirurgen zur Überwachungsstrategie bei Patienten mit langjähriger Colitis ulcerosa zur Verhinderung des Colitiskarzinoms werden diskutiert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Actis GC, Ottobrelli A, Pera A et al (1993) Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative Colitis without the need for highdose steroids. J Clin Gastroenterol 17:10–13

    Article  PubMed  CAS  Google Scholar 

  2. Ardizzone S, Bianchi Porro G (1996) The topical treatment of distal ulcerative Colitis. Europ J Gastroenterol Hepatol 8:599–602

    Article  CAS  Google Scholar 

  3. Best WR, Becktel JM, Singleton JW, Kern FJ (1976) Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology 70:439–444

    PubMed  CAS  Google Scholar 

  4. Bianchi Porro G, Ardizzone S, Petrillo M, Fasoli A, Molteni P, Imbesi V (1995) Low pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative Colitis: a randomized, double-blind study. Am J Gastroenterol 90:736–739

    PubMed  CAS  Google Scholar 

  5. Bouhnik Y, Lemann M, Mary J, Scemama G, Tai R, Matuchansky C et al (1996) Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptorurine. Lancet 347:215–219

    Article  PubMed  CAS  Google Scholar 

  6. Brandt LJ, Bernstein LH, Boley SJ, Frank MS (1982) Metronidazole therapy for perianal Crohn’s disease: a follow-up study. Gastroenterology 83:383–387

    PubMed  CAS  Google Scholar 

  7. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, Schaffalitzky de Muckadell O, Williams N et al (1989) A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. New Engl J Med 321: 845–850

    Article  PubMed  CAS  Google Scholar 

  8. Butzner JD, Parmar R, Bell CJ, Dalal V (1996) Butyrate enema therapy: stimulates mucosal repair in experimental Colitis in the rat. Gut 38:568–573

    Article  PubMed  CAS  Google Scholar 

  9. Choi PM, Targan SR (1994) Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sei 39:1885–1892

    Article  CAS  Google Scholar 

  10. Egan LJ, Sandborn WJ (1996) Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 71:69–80

    Article  PubMed  CAS  Google Scholar 

  11. Ekbom AM (1995) Cancer risk in inflammatory bowel disease. Can J Gastroenterol 9: 23–26

    Google Scholar 

  12. Engelhardt K, Mohr K (1995) Mesalazin. Dtsch med Wschr 120:769–770

    PubMed  CAS  Google Scholar 

  13. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G et al (1993) Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 105:367–372

    PubMed  CAS  Google Scholar 

  14. Feagan BG (1996) Oral budesonide therapy for ulcerative Colitis: a topical tale. Gastroenterology 110:2000–2002

    Article  PubMed  CAS  Google Scholar 

  15. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L et al (1995) Methotrexate for the treatment of Crohn’s disease. New Engl J Med 332: 292–297

    Article  PubMed  CAS  Google Scholar 

  16. Fernändez-Banares F, Cabre E, Esteve-Comas M, Gassuli MA (1995) How effective is enteral nutrition in inducing clinical remission in active Crohn’s disease? A meta-analysis of the randomized clinical trials. J Parenter Enter Nutr 19:356–364

    Article  Google Scholar 

  17. Gomes P, du Bouley C, Smith CL, Holdstock G (1986) Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 27: 92–95

    Article  PubMed  CAS  Google Scholar 

  18. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN et al (1994) Oral budesonide for active Crohn’s disease. New Engl J Med 331: 836–841

    Article  PubMed  CAS  Google Scholar 

  19. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN et al (1996) Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Gastroenterology 110:45–51

    Article  PubMed  CAS  Google Scholar 

  20. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR (1995) Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology 108: 1056–1067

    Article  PubMed  CAS  Google Scholar 

  21. Hanauer SB (1996) Inflammatory bowel disease. New Engl J Med 334: 841–848

    Article  PubMed  CAS  Google Scholar 

  22. Hodgson HJF, Mazlam MZ (1991) Assessment of drug therapy in inflammatory bowel disease. Aliment Pharmacol Therap 5:555–584

    Article  CAS  Google Scholar 

  23. Kozarek RA (1996) Methotrexate and ulcerative Colitis: wrong drug? wrong dose? or wrong disease? Gastroenterology 110:1652–1656

    Article  PubMed  CAS  Google Scholar 

  24. Lee FI, Jewell DP, Mani V, Keighley RB, Kingston RD, Record CO et al (1996) A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative Colitis. Gut 38:229–233

    Article  PubMed  CAS  Google Scholar 

  25. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G et al (1994) Cyclosporine in severe ulcerative Colitis refractory to Steroid therapy. New Engl J Med 330: 1841–1845

    Article  PubMed  CAS  Google Scholar 

  26. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP et al (1996) Risk of colorectal neoplasia in patients with sclerosing Cholangitis. Gastroenterology 110:432–440.

    Article  PubMed  Google Scholar 

  27. Löfberg R, Danielsson A, Suhr O, Nilsson A, Schöler R, Nyberg A et al (1996) Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative Colitis. Gastroenterology 110:1713–1718

    Article  PubMed  Google Scholar 

  28. Löfberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G et al (1996) Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease. A placebo controlled one year study. Gut 39:82–86

    Article  PubMed  Google Scholar 

  29. Mansfield JC, Giaffer MH, Holdsworth CD (1995) Controlled trial of Oligopeptide versus amino acid diet in treatment of active Crohn’s disease. Gut 36:60–66

    Article  PubMed  CAS  Google Scholar 

  30. McLeod RS, Wolff BG, Steinhart AH, Carryer PW, O’Rourke K, Andrews DF et al (1995) Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn’s disease. Gastroenterology 109:404–413.

    Article  PubMed  CAS  Google Scholar 

  31. Modigliani R, Colombel JF, Dupas J, Dapoigny W, Costil V, Veyrac M et al (1996) Mesalamine in Crohn’s disease with steroid-induced remission: effect on Steroid withdrawal and remission maintenance. Gastroenterology 110:688–693

    Article  PubMed  CAS  Google Scholar 

  32. Mulder CJJ, Fockens P, Meijer JWR, van der Heide H, Wiltink EHH, Tytgat GNJ (1996) Beclomethasone diproprionate (3 mg) versus 5-aminosalicylic acid (2 g) versus combination of both (3 mg/2 g) as rentention enemas in active ulcerative proctitis. Europ J Gastroenterol Hepatol 8:549–553

    Article  CAS  Google Scholar 

  33. Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med 123:132–142

    PubMed  CAS  Google Scholar 

  34. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H (1994) Risk factor for colorectal cancer in patients with ulcerative Colitis: a case-control study. Gastroenterology 107:117–120

    PubMed  CAS  Google Scholar 

  35. Provenzale D, Kowdley K, Arora S, Wong JB (1995) Prophylactic colectomy or surveillance for chronic ulcerative Colitis? A decision analysis. Gastroenterology 109:1188–1196

    Article  PubMed  CAS  Google Scholar 

  36. Riley SAS, Mani V, Goodman MJ, Dutt S, Herd ME (1991) Microscopic activity in ulcerative Colitis: what does it mean? Gut 32:174–178

    Article  PubMed  CAS  Google Scholar 

  37. Royall D, Jeejeebhoy KN, Baker JP, Allard JP, Habal FM, Cunnane SC et al (1994) Comparison of amino acid v peptide based enteral diets in active Crohn’s disease: clinical and nutritional outcome. Gut 35:783–787

    Article  PubMed  CAS  Google Scholar 

  38. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R et al (1995) Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108:1617–1621

    Article  PubMed  CAS  Google Scholar 

  39. Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D et al (1994) A comparison of budesonide with prednisolone for active Crohn’s disease. New Engl J Med 331:842–845

    Article  PubMed  CAS  Google Scholar 

  40. Sachar DB (1996) Maintenance strategies in Crohn’s disease. Hosp Pract: 99–106

    Google Scholar 

  41. Sandborn WJ (1995) Cyclosporine therapy for inflammatory bowel disease: definite answers and remaining questions. Gastroenterology 109:1001–1003

    Article  PubMed  CAS  Google Scholar 

  42. Sandborn WJ, Van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ (1995) An intravenous loading dose of azathioprine decreases time to response in patients with Crohn’s disease. Gastroenterology 109:1808–1817

    Article  PubMed  CAS  Google Scholar 

  43. Sartor RB (1994) Cyclosporine therapy for inflammatory bowel disease. New Engl J Med 330: 1897–1898

    Article  PubMed  CAS  Google Scholar 

  44. Spencer CM, McTavish D (1995) Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50:854–872

    Article  PubMed  CAS  Google Scholar 

  45. Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G, Smith PR et al (1995) European trial of cyclosporine in chronic active Crohn’s disease: A 12-month study. Gastroenterology 109:774–782

    Article  PubMed  CAS  Google Scholar 

  46. Teahon K, Pearson M, Levi J, Bjarnason I (1995) Practical aspects of enteral nutrition in the management of Crohn’s disease. J Parenter Enter Nutr 19:365–368

    Article  CAS  Google Scholar 

  47. Truelove SC, Witts LJ (1955) Cortisone in ulcerative Colitis: final report on a therapeutic trial. Brit Med J 2:1041–1048

    Article  PubMed  CAS  Google Scholar 

  48. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD et al (1997) Colorectal cancer Screening: clinical guidelines and rationale. Gastroenterology 112:594–642

    Article  PubMed  CAS  Google Scholar 

  49. Winawer SJ, St. John DJ, Bond JH (1995) Prevention of colorectal cancer: Guidelines based on new data. Bull WHO 73: 7–10

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik II, Universitätsklinikum, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Deutschland

    W. F. Caspary

Authors
  1. W. F. Caspary
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Deutschen Gesellschaft für Chirurgie, Steinhölzle 16, D-89197, Westerstetten-Vorderdenkental, Deutschland

    W. Hartel (Generalsekretär) (Generalsekretär)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Caspary, W.F. (1997). Interdisziplinäre Leitlinien: Entzündliche Darmerkrankungen — M. Crohn, Colitis ulcerosa. In: Hartel, W. (eds) Klinik und Forschung in der Chirurgie unter dem Aspekt von Effizienz und Ökonomie. Langenbecks Archiv für Chirurgie, vol 1997. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60881-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60881-0_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63332-7

  • Online ISBN: 978-3-642-60881-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation